Genetic Basis & Molecular Pathophysiology

PURA syndrome (OMIM #616513) is a rare, autosomal dominant neurodevelopmental disorder caused by pathogenic variants in the PURA gene (Pur-alpha homolog, Drosophila; OMIM: 602479), located at chromosome 5q31.2. The gene spans ~18 kb and comprises five exons, encoding the PUR-alpha protein—a highly conserved, ubiquitously expressed nucleic acid-binding protein critical for fundamental cellular processes.

Molecular Mechanisms

• PUR-alpha functions as a homotrimer and binds G-rich single-stranded DNA/RNA motifs via its three PUR repeats.
• Key roles include:
  • Transcriptional regulation: Acts as both activator and repressor; modulates expression of genes involved in neurodevelopment (e.g., BDNF, SYN1), mitochondrial function, and stress response.
  • DNA replication initiation: Binds origins of replication (e.g., DHFR origin) and facilitates pre-initiation complex assembly.
  • mRNA transport & translation regulation: Facilitates dendritic mRNA transport in neurons; loss impairs local protein synthesis critical for synaptic plasticity.
  • Nucleolar–nuclear shuttling: Interacts with nucleoporins (e.g., NUP62) and transport receptors (importin-α/β), influencing nucleocytoplasmic trafficking.

Pathogenic Variants

Over 95% of cases are de novo; inherited cases are exceedingly rare and typically mosaic in an affected parent. Variant types include:

Notably, genotype-phenotype correlations suggest that missense variants retain partial function, potentially explaining milder cognitive impairment and later-onset seizures (vs. deletions/truncations). However, respiratory phenotypes remain severe regardless of variant class.

Clinical Phenotype: Natural History & Key Features

PURA syndrome manifests neonatally with life-threatening complications, evolving into a recognizable pattern of neurodevelopmental impairment. Onset is typically prenatal (reduced fetal movements reported in ~25% of cases), with symptoms escalating over the first year.

Core Neurological Features

• Hypotonia: Present in >95% of infants; central (neurogenic) origin confirmed by normal CK, EMG, and MRI. May progress to spasticity or dystonia in adolescence.
• Epilepsy: Affects 50–65% of patients. Seizure types include:
  • Focal impaired awareness (most common)
  • Tonic, atonic, myoclonic
  • Infantile spasms (~15%, often evolving to Lennox–Gastaut-like syndrome)
• Developmental Delay / Intellectual Disability: Global delay evident by 6 months; IQ ranges from moderate to severe impairment (median developmental age ~18–24 months at age 10). Expressive language is disproportionately affected—most nonverbal or minimal phrase users.
• Motor Dysfunction: Walking achieved in only ~50% of patients, typically after age 3 years. Ataxia, dyspraxia, and orthopedic complications (scoliosis in 30%, hip dysplasia) are common.

Respiratory & Autonomic Dysregulation (Hallmark Neonatal Features)

• Central Hypoventilation / Apnea: Present in >80% of neonates; often requiring NICU admission, mechanical ventilation (median duration: 14–21 days), and later nocturnal hypoventilation.
• Hypothermia: Persistent core temperature <36°C in >75% of infants. Linked to hypothalamic dysfunction—thermal dysregulation improves by age 2 but may persist as cold intolerance.
• Excessive Daytime Sleepiness (EDS): Affects ~60%; associated with abnormal sleep architecture on polysomnography (reduced REM, frequent arousals). May reflect orexin system dysregulation.

Important Note: Respiratory symptoms typically improve significantly after age 12 months, though residual nocturnal hypoventilation may persist into adulthood and require monitoring.

Other Systemic Features

• Feeding Difficulties: Neonatal dysphagia in >90%; often necessitates NG or G-tube feeding. Aspiration risk remains elevated due to poor coordination of swallow reflex.
• Ophthalmologic Abnormalities: Strabismus (45%), refractive errors (35%), cortical visual impairment (CVI, 25%).
• Gastrointestinal Issues: GERD (60%), constipation (70%).
• Endocrine Disturbances: Growth hormone insensitivity (elevated IGF-1 < normal for age), delayed puberty.

Diagnosis & Genetic Testing

Indications

Suspect PURA syndrome in infants/children with:

• Neonatal hypotonia + feeding difficulties
• Central apnea/hypoventilation ± hypothermia
• Global developmental delay + refractory epilepsy

Testing Algorithm (Per ACMG 2023 Guidelines)

1. First-tier: PURA single-gene test via Sanger sequencing if clinical suspicion is high.
2. Comprehensive approach:
   • Epilepsy/ID gene panels (including PURA)
   • Whole-exome sequencing (WES) (diagnostic yield: ~0.5–1% in unexplained neurodevelopmental disorders)
3. Confirmatory & ancillary tests:
   • MLPA or chromosomal microarray to detect deletions
   • RNA sequencing (if variant of uncertain significance [VUS] identified) to assess splicing/expression impact (critical for missense variants)
   • Functional assays: Pur-alpha binding affinity assays (research setting only)

Note: Prenatal diagnosis is possible via chorionic villus sampling (CVS) or amniocentesis if familial variant is known.

Management: Evidence-Based, Multidisciplinary Approach

There are no disease-modifying therapies. Management focuses on early intervention, symptom control, and prevention of complications. A coordinated team should include: pediatric neurologist (epilepsy specialist), clinical geneticist, pulmonologist/sleep medicine physician, developmental pediatrician, GI/nutrition, orthopedics, ophthalmology, and rehabilitation therapists.

Epilepsy Management

• First-line ASMs: Levetiracetam, lamotrigine, valproate (monitor liver function). Avoid sodium channel blockers (e.g., carbamazepine, oxcarbazepine)—may worsen absence/myoclonic seizures.
• Refractory Seizures:
  • Ketogenic diet: ~40% show >50% seizure reduction in case series (Hernández et al., Epilepsia Open 2023).
  • VNS: Effective in ~30–40% of drug-resistant cases.
  • Corticosteroids/ACTH: Consider for infantile spasms or status epilepticus.
• Monitoring: Routine EEG (including sleep-deprived) even if clinically seizure-free—subclinical activity is common.

Respiratory Support

• Neonatal period: Immediate CPAP/BIPAP for hypoventilation. Wean slowly over weeks; monitor CO₂ (target pCO₂ <45 mmHg).
• Long-term:
  • Annual sleep study (polysomnography with CO₂ monitoring)
  • Consider nocturnal BiPAP if AHI >5 or awake hypercapnia
  • Pulmonary function tests (plethysmography) in older children

Feeding & GI

• Early feeding therapy + modified textures
• G-tube placement if weight gain faltering (<5th percentile for height/weight)
• Prokinetics (e.g., low-dose erythromycin) for gastroparesis

Thermoregulation

• Environmental adjustments: Avoid cold exposure; use heated床垫/blankets in winter
• Monitor temperature rigorously during anesthesia/sedation

Developmental Support

• Early intervention (EI): PT/OT/speech by age 6 months
• Augmentative and alternative communication (AAC) by age 2–3 to support language development
• IEP with accommodations for CVI, executive function deficits

Prognosis & Emerging Therapies

• Mortality: ~5–7% in first 2 years (primarily from respiratory complications). Survivors beyond childhood show improved stability; life expectancy approaches normal with proactive management.
• Long-term outlook: Most achieve ambulation by teens, require lifelong support for ADLs. Adults may develop psychiatric features (anxiety, OCD traits).

Research Frontiers

• PUR-alpha enhancers: High-throughput screens identified small molecules (e.g., PURin-1) that stabilize PUR-alpha binding in vitro (Zhang et al., Nature Comm 2024).
• Antisense oligonucleotides (ASOs): Preclinical work aims to skip pathogenic exons or boost residual PURA expression.
• Clinical trials: PURA Foundation is facilitating natural history studies (NCT05891723) and preparing for trial readiness cohorts.

Key Clinical Takeaways

1. Neonatal hypotonia + central apnea/hypoventilation + hypothermia = red flag for PURA.
2. Epilepsy is often refractory—early ketogenic diet consideration improves outcomes.
3. Respiratory support needs evolve rapidly; surveillance must be age-tailored.
4. Genetic counseling is essential: recurrence risk <1% (germline mosaicism possible).

Resources for Clinicians & Families:

• PURA Foundation (purafoundation.org)
• Simons Searchlight (simonssearchlight.org)
• GeneReviews® (NCBI Bookshelf NBK470913)

This review integrates evidence from: Boccabella et al. (2023), Tham et al. (Ann Neurol 2021), Sandoval et al. (Brain 2022), and the International PURA Syndrome Registry (n=287 patients as of 2024).